Clinical Trials

NRG -HN004 Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin (15-JAN-2019)


Study ID
NRG-HN004

NCT Number
NCT03258554 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0626

Principle Investigator
Dr. Alter, Robert

Phase
II/III

Sponsor
NRG Oncology


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now